I-Mab Biopharma (IMAB) Misses Q3 EPS by 4c

I-Mab Biopharma (NASDAQ: IMAB) reported Q3 EPS of ($0.11), $0.04 worse than the analyst estimate of ($0.07).

For earnings history and earnings-related data on I-Mab Biopharma (IMAB) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• ResMed names Carol Burt as lead director as Ron Taylor retires
• Golden Spike Resources plans name change, share consolidation and C$500K raise